Total Payments
$186,602
2024 Payments
$48,728
Companies
17
Transactions
256
Medicare Patients
981
Medicare Billing
$118,868
Payment Breakdown by Category
Other$124,926 (66.9%)
Research$26,238 (14.1%)
Consulting$19,465 (10.4%)
Travel$11,967 (6.4%)
Food & Beverage$3,996 (2.1%)
Education$10.66 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $62,938 | 40 | 33.7% |
| Honoraria | $61,988 | 23 | 33.2% |
| Unspecified | $26,238 | 44 | 14.1% |
| Consulting Fee | $19,465 | 8 | 10.4% |
| Travel and Lodging | $11,967 | 60 | 6.4% |
| Food and Beverage | $3,996 | 80 | 2.1% |
| Education | $10.66 | 1 | 0.0% |
Payments by Type
General
$160,364
212 transactions
Research
$26,238
44 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SK Life Science, Inc. | $69,512 | 63 | $0 (2024) |
| UCB, Inc. | $60,838 | 100 | $0 (2024) |
| Greenwich Biosciences, Inc. | $17,970 | 19 | $0 (2020) |
| Sunovion Pharmaceuticals Inc. | $7,717 | 11 | $0 (2018) |
| UCB SA | $7,650 | 2 | $0 (2023) |
| Neurelis, Inc. | $6,450 | 6 | $0 (2020) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $6,300 | 12 | $0 (2019) |
| Eisai Inc. | $4,260 | 7 | $0 (2017) |
| BIOCODEX, INC. | $1,895 | 1 | $0 (2022) |
| Biogen, Inc. | $1,456 | 14 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $48,728 | 35 | SK Life Science, Inc. ($43,428) |
| 2023 | $22,450 | 21 | SK Life Science, Inc. ($18,650) |
| 2022 | $2,009 | 2 | BIOCODEX, INC. ($1,895) |
| 2021 | $7,931 | 7 | UCB, Inc. ($3,960) |
| 2020 | $37,155 | 67 | UCB, Inc. ($20,371) |
| 2019 | $24,690 | 37 | Greenwich Biosciences, Inc. ($15,894) |
| 2018 | $18,567 | 23 | UCB, Inc. ($16,128) |
| 2017 | $25,072 | 64 | UCB, Inc. ($12,997) |
All Payment Transactions
256 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Honoraria | Cash or cash equivalent | $5,950.00 | General |
| Category: Neurology | ||||||
| 12/20/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Honoraria | Cash or cash equivalent | $1,750.00 | General |
| Category: Neurology | ||||||
| 12/20/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Travel and Lodging | In-kind items and services | $321.79 | General |
| Category: Neurology | ||||||
| 12/20/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Travel and Lodging | In-kind items and services | $48.24 | General |
| Category: Neurology | ||||||
| 12/20/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Food and Beverage | Cash or cash equivalent | $22.98 | General |
| Category: Neurology | ||||||
| 12/10/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Food and Beverage | In-kind items and services | $140.35 | General |
| Category: Neurology | ||||||
| 12/09/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Food and Beverage | In-kind items and services | $45.83 | General |
| Category: NEUROLOGY | ||||||
| 11/13/2024 | NEUROPACE, INC. | RNS Neurostimulator Kit (Device) | Food and Beverage | In-kind items and services | $20.95 | General |
| Category: Epilepsy | ||||||
| 10/27/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Honoraria | Cash or cash equivalent | $700.00 | General |
| Category: Neurology | ||||||
| 10/22/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Honoraria | Cash or cash equivalent | $4,900.00 | General |
| Category: Neurology | ||||||
| 10/22/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Travel and Lodging | In-kind items and services | $416.95 | General |
| Category: Neurology | ||||||
| 10/10/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Food and Beverage | In-kind items and services | $113.17 | General |
| Category: NEUROLOGY | ||||||
| 07/25/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Food and Beverage | Cash or cash equivalent | $127.57 | General |
| Category: Neurology | ||||||
| 07/25/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Travel and Lodging | Cash or cash equivalent | $69.20 | General |
| Category: Neurology | ||||||
| 07/25/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Travel and Lodging | Cash or cash equivalent | $24.12 | General |
| Category: Neurology | ||||||
| 07/18/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Honoraria | Cash or cash equivalent | $8,400.00 | General |
| Category: Neurology | ||||||
| 07/18/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Travel and Lodging | In-kind items and services | $510.00 | General |
| Category: Neurology | ||||||
| 06/27/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Honoraria | Cash or cash equivalent | $4,900.00 | General |
| Category: Neurology | ||||||
| 06/27/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Travel and Lodging | In-kind items and services | $470.87 | General |
| Category: Neurology | ||||||
| 06/27/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Travel and Lodging | In-kind items and services | $268.45 | General |
| Category: Neurology | ||||||
| 06/27/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Food and Beverage | In-kind items and services | $123.88 | General |
| Category: Neurology | ||||||
| 06/26/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Honoraria | Cash or cash equivalent | $4,900.00 | General |
| Category: Neurology | ||||||
| 06/26/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Travel and Lodging | In-kind items and services | $470.87 | General |
| Category: Neurology | ||||||
| 06/26/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Travel and Lodging | In-kind items and services | $268.45 | General |
| Category: Neurology | ||||||
| 06/26/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Travel and Lodging | Cash or cash equivalent | $97.41 | General |
| Category: Neurology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase 2 OPC-214870 Epilepsy study | Otsuka Pharmaceutical Development & Commercialization, Inc. | $4,661 | 3 |
| "A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR UNCONTROLLED PRIMARY GENERALIZED TONIC-CLO" | UCB, Inc. | $2,300 | 1 |
| Efficacy and safety of adjunctive lacosamide in the treatment of primary generalized tonic-clonic seizures a double-blind, randomized, placebo-controlled trial | UCB, Inc. | $2,300 | 1 |
| Efficacy and safety of adjunctive lacosamide in the treatment of primary generalized tonic-clonic seizures: a double-blind, randomized, placebo-controlled trial | UCB, Inc. | $2,300 | 1 |
| Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy | Biogen, Inc. | $1,456 | 14 |
| Efficacy and tolerability of adjunctive lacosamide in the treatment of primary generalized tonic-clonic seizures a double-blind, randomized, placebo-controlled trial | UCB, Inc. | $1,240 | 1 |
| Efficacy and tolerability of adjunctive lacosamide in the treatment of primary generalized tonic-clonic seizures: a double-blind, randomized, placebo-controlled trial | UCB, Inc. | $1,240 | 1 |
| AN OPEN-LABEL, MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR UNCONTROLLED PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN SUBJECTS WITH | UCB, Inc. | $840.00 | 2 |
| A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR UNCONTROLLED PRIMARY GENERALIZED TONIC-CLO | UCB, Inc. | $820.00 | 2 |
| Efficacy and tolerability of adjunctive lacosamide in the treatment of pediatric patients with primary generalized tonic-clonic seizures subgroup analysis of a double-blind, randomized, placebo-controlled trial | UCB, Inc. | $820.00 | 1 |
| Efficacy and tolerability of adjunctive lacosamide in the treatment of pediatric patients with primary generalized tonic-clonic seizures: subgroup analysis of a double-blind, randomized, placebo-controlled trial | UCB, Inc. | $820.00 | 1 |
| Long-term safety and efficacy of adjunctive lacosamide in the treatment of primary generalized tonic-clonic seizures an open-label extension trial | UCB, Inc. | $820.00 | 1 |
| Long-term safety and efficacy of adjunctive lacosamide in the treatment of primary generalized tonic-clonic seizures: an open-label extension trial | UCB, Inc. | $820.00 | 1 |
| Efficacy and tolerability of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures a double-blind, randomized, placebo-controlled trial | UCB, Inc. | $420.00 | 1 |
| Efficacy and tolerability of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures: a double-blind, randomized, placebo-controlled trial | UCB, Inc. | $420.00 | 1 |
| Efficacy and tolerability of adjunctive lacosamide in the treatment of primary generalized tonic-clonic seizures a randomized controlled trial | UCB, Inc. | $420.00 | 1 |
| Efficacy and tolerability of adjunctive lacosamide in the treatment of primary generalized tonic-clonic seizures: a randomized controlled trial | UCB, Inc. | $420.00 | 1 |
| Efficacy of adjunctive lacosamide in the treatment of primary generalized tonic-clonic seizures subgroup analyses of a double-blind, randomized, placebo-controlled trial | UCB, Inc. | $420.00 | 1 |
| Efficacy of adjunctive lacosamide in the treatment of primary generalized tonic-clonic seizures: subgroup analyses of a double-blind, randomized, placebo-controlled trial | UCB, Inc. | $420.00 | 1 |
| Long-term safety and efficacy of adjunctive lacosamide in adults with focal-onset seizures interim analysis of the post-marketing surveillance | UCB, Inc. | $420.00 | 1 |
| Long-term safety and efficacy of adjunctive lacosamide in adults with focal-onset seizures: interim analysis of the post-marketing surveillance | UCB, Inc. | $420.00 | 1 |
| Safety of adjunctive lacosamide in patients with primary generalized tonic-clonic seizures (PGTCS) and patients with focal seizures: pooled data for pediatrics and adults | UCB, Inc. | $420.00 | 1 |
| Safety of adjunctive lacosamide in patients with primary generalized tonic-clonic seizures PGTCS and patients with focal seizures pooled data for pediatrics and adults | UCB, Inc. | $420.00 | 1 |
| Efficacy of adjunctive lacosamide in the treatment of primary generalized tonic-clonicseizures subgroup analyses of a double-blind, randomized, placebo-controlled trial | UCB, Inc. | $400.00 | 1 |
| Efficacy of adjunctive lacosamide in the treatment of primary generalized tonic-clonicseizures: subgroup analyses of a double-blind, randomized, placebo-controlled trial | UCB, Inc. | $400.00 | 1 |
| Safety of adjunctive lacosamide in patients with primary generalized tonic-clonicseizures and patients with focal seizures pooled data for pediatrics and adults | UCB, Inc. | $400.00 | 1 |
| Safety of adjunctive lacosamide in patients with primary generalized tonic-clonicseizures and patients with focal seizures: pooled data for pediatrics and adults | UCB, Inc. | $400.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 164 | 221 | $95,048 | $18,313 |
| 2022 | 6 | 264 | 372 | $145,377 | $30,300 |
| 2021 | 7 | 249 | 398 | $154,108 | $36,721 |
| 2020 | 8 | 304 | 424 | $157,306 | $33,534 |
Total Patients
981
Total Services
1,415
Medicare Billing
$118,868
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 80 | 107 | $13,158 | $6,661 | 50.6% |
| 95720 | Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | Facility | 2023 | 20 | 40 | $46,360 | $6,309 | 13.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 36 | 46 | $8,538 | $4,075 | 47.7% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2023 | 28 | 28 | $26,992 | $1,269 | 4.7% |
| 95720 | Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | Facility | 2022 | 26 | 56 | $64,904 | $9,722 | 15.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 82 | 121 | $15,710 | $7,658 | 48.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 44 | 70 | $12,658 | $7,646 | 60.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 55 | 64 | $5,769 | $2,773 | 48.1% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2022 | 46 | 47 | $45,104 | $2,140 | 4.7% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 11 | 14 | $1,232 | $360.49 | 29.3% |
| 95720 | Continuous measurement of brain wave activity with video (veeg), 12-26 hours, with health care professional analysis, interpretation and report | Facility | 2021 | 23 | 74 | $85,766 | $12,560 | 14.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 76 | 129 | $17,436 | $9,178 | 52.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 49 | 77 | $13,635 | $8,474 | 62.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 49 | 65 | $6,383 | $2,684 | 42.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 13 | 13 | $2,652 | $1,906 | 71.9% |
| 95816 | Measurement and recording of brain wave (eeg) activity, awake and drowsy | Facility | 2021 | 28 | 28 | $26,992 | $1,322 | 4.9% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 11 | 12 | $1,244 | $596.67 | 48.0% |
| 95720 | Continuous measurement of brain wave activity with video (veeg), 12-26 hours, with health care professional analysis, interpretation and report | Facility | 2020 | 24 | 51 | $59,109 | $9,190 | 15.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 93 | 153 | $16,124 | $8,365 | 51.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 61 | 91 | $13,343 | $7,354 | 55.1% |
| 95816 | Measurement and recording of brain wave (eeg) activity, awake and drowsy | Facility | 2020 | 55 | 55 | $46,084 | $2,729 | 5.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 15 | 15 | $3,075 | $1,883 | 61.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 22 | 24 | $2,816 | $1,594 | 56.6% |
| 95718 | Continuous measurement of brain wave activity with video (veeg), 2-12 hours, with health care professional analysis, interpretation and report | Facility | 2020 | 13 | 13 | $15,067 | $1,537 | 10.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 21 | 22 | $1,688 | $882.26 | 52.3% |
About Dr. David Vossler, MD
Dr. David Vossler, MD is a Neurology healthcare provider based in Renton, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1831136985.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Vossler, MD has received a total of $186,602 in payments from pharmaceutical and medical device companies, with $48,728 received in 2024. These payments were reported across 256 transactions from 17 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($62,938).
As a Medicare-enrolled provider, Vossler has provided services to 981 Medicare beneficiaries, totaling 1,415 services with total Medicare billing of $118,868. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Renton, WA
- Active Since 05/31/2006
- Last Updated 11/17/2008
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1831136985
Products in Payments
- XCOPRI (Drug) $62,625
- Briviact (Drug) $34,057
- Vimpat (Drug) $23,765
- Epidiolex (Drug) $17,970
- APTIOM (Drug) $7,692
- Cenobamate (Drug) $6,834
- VALTOCO (Drug) $6,450
- Fintepla (Drug) $5,120
- Fycompa (Drug) $4,260
- DIACOMIT (Drug) $1,895
- TYSABRI (Biological) $1,456
- ONFI (Drug) $987.50
- ACTIVA (Device) $845.27
- EPIDIOLEX (Drug) $272.79
- Aimovig (Biological) $232.97
- NURTEC ODT (Drug) $120.70
- RNS Neurostimulator Kit (Device) $20.95
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Renton
Dr. Ali Sultan-Qurraie, M.d, M.D
Neurology — Payments: $32,702
Neurology $32,702
Jennifer Han, M.d, M.D
Neurology — Payments: $984.52
Neurology $984.52
Krista Kawaguchi, M.d, M.D
Neurology — Payments: $552.82
Neurology $552.82
Don Thai, Md, MD
Neurology — Payments: $494.03
Neurology $494.03
Dr. Chang Shin, M.d, M.D
Neurology — Payments: $202.34
Neurology $202.34
Alexey Shikuev, Md, MD
Neurology — Payments: $199.91
Neurology $199.91